World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 112 5087 4773 200 190 619 56178

Kim Papp publications per year

The chart shows the history of publications by Kim Papp between 1990 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Kim Papp published across 37 years, from 1990 to 2026, averaging 21.5 papers a year. Output peaked at 94 publications in 2021. 55 of the 797 publications appeared in the last two years.

No. of publications
20 40 60 80
Bar chart. Horizontal axis: year, 1990 to 2026. Vertical axis: number of publications, 0 to 94. Peak 94 publications in 2021. 1990: 1 publication 1991: 1 publication 1992: 0 publications 1993: 0 publications 1994: 0 publications 1995: 0 publications 1996: 0 publications 1997: 1 publication 1998: 1 publication 1999: 2 publications 2000: 2 publications 2001: 2 publications 2002: 4 publications 2003: 3 publications 2004: 13 publications 2005: 18 publications 2006: 14 publications 2007: 12 publications 2008: 17 publications 2009: 14 publications 2010: 16 publications 2011: 20 publications 2012: 28 publications 2013: 21 publications 2014: 8 publications 2015: 29 publications 2016: 33 publications 2017: 41 publications 2018: 58 publications 2019: 39 publications 2020: 65 publications 2021: 94 publications 2022: 57 publications 2023: 70 publications 2024: 58 publications 2025: 54 publications 2026: 1 publication
1990 2026

797 publications in total across all disciplines

View publications per year as a table
Kim Papp: publications per year, 1990 to 2026
Year Publications
1990 1
1991 1
1992 0
1993 0
1994 0
1995 0
1996 0
1997 1
1998 1
1999 2
2000 2
2001 2
2002 4
2003 3
2004 13
2005 18
2006 14
2007 12
2008 17
2009 14
2010 16
2011 20
2012 28
2013 21
2014 8
2015 29
2016 33
2017 41
2018 58
2019 39
2020 65
2021 94
2022 57
2023 70
2024 58
2025 54
2026 1
Total 797
Download as CSV

Kim Papp publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kim Papp sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 601–620 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 619 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396 619
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Kim Papp D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kim Papp sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 112–113 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 112 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399 112
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Kim Papp is affiliated with Probity Medical Research in Canada and has contributed extensively to the fields of medicine, immunology, and dermatology. Their research productivity spans multiple areas such as immunology, rheumatology, pediatrics, and allergy, with a focus on skin diseases and autoimmune conditions.

The primary research domains include:

  • Medicine
  • Immunology and Microbiology

Within these domains, subfields of study highlight:

  • Immunology
  • Dermatology
  • Rheumatology
  • Immunology and Allergy
  • Pediatrics, Perinatology and Child Health

Papp's research topics cover a broad spectrum of dermatological and immunological issues, with an emphasis on clinical treatment and pharmaceutical research. The main subjects of their work include:

  • Psoriasis: Treatment and Pathogenesis
  • Dermatology and Skin Diseases
  • Pharmaceutical Studies and Practices
  • Autoimmune Bullous Skin Diseases
  • Health Systems, Economic Evaluations, Quality of Life
  • Asthma and Respiratory Diseases
  • Allergic Rhinitis and Sensitization

Their frequent collaborators indicate active engagement in multidisciplinary research. Notable co-authors are:

  • Melinda Gooderham
  • Andrew Blauvelt
  • Mark Lebwohl
  • Leon Kircik
  • Linda Stein Gold

Papp has published in a number of dermatology and medical journals. The most recurrent venues for their work include:

  • Journal of the American Academy of Dermatology
  • SKIN The Journal of Cutaneous Medicine
  • Dermatology and Therapy
  • British Journal of Dermatology
  • Journal of the European Academy of Dermatology and Venereology

Recent publications by Kim Papp illustrate the focus on clinical trials and therapeutic interventions for skin diseases. Selected papers include:

  • "Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials," 2021, The Lancet
  • "Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial," 2022, Journal of the American Academy of Dermatology
  • "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial," 2021, The Lancet
  • "Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies," 2021, Journal of the American Academy of Dermatology
  • "Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial," 2022, Journal of the American Academy of Dermatology

Best Publications

  • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

    Craig L Leonardi;Alexa B Kimball;Kim A Papp;Newman Yeilding

  • Secukinumab in plaque psoriasis--results of two phase 3 trials.

    Richard G. Langley;Boni E. Elewski;Mark Lebwohl;Kristian Reich

  • Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    Andrew Blauvelt;Marjolein de Bruin-Weller;Melinda Gooderham;Jennifer C. Cather

  • Infliximab induction and maintenance therapy for moderate-to-severe psoriasis : a phase III, multicentre, double-blind trial

    Kristian Reich;Frank O Nestle;Kim Papp;Jean-Paul Ortonne

  • Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

    Stephen Tyring;Alice Gottlieb;Kim Papp;Ken Gordon

  • Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

    Kim A Papp;Craig Leonardi;Alan Menter;Jean-Paul Ortonne

  • Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    Alan Menter;Stephen K. Tyring;Kenneth Gordon;Alexa B. Kimball

  • Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Mark Lebwohl;Bruce Strober;Alan Menter;Kenneth Gordon

  • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

    Andrew Blauvelt;Kim A. Papp;Christopher E.M. Griffiths;Bruce Randazzo;Bruce Randazzo

  • A global phase III randomized controlled trial of etanercept in psoriasis : safety, efficacy, and effect of dose reduction

    Kim A. Papp;S. Tyring;M. Lahfa;J. Prinz

  • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    Christopher E M Griffiths;Kristian Reich;Mark Lebwohl;Peter van de Kerkhof

  • Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

    Jean-Hilaire Saurat;G. Stingl;L. Dubertret;K. Papp

  • Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Kenneth B Gordon;Jean-Frederic Colombel;Dana S Hardin

  • Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

    Arthur Kavanaugh;Iain McInnes;Philip Mease;Gerald G. Krueger

  • Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

    Alexa B Kimball;Martin M Okun;David A Williams;Alice B Gottlieb

  • Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

    Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  • Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Kim Papp;Kristian Reich;Craig L. Leonardi;Leon Kircik

  • A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis

    Alan Menter;Steven R. Feldman;Gerald D. Weinstein;Kim Papp

  • Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)

    Michelle A. Lowes;Francesca Chamian;Maria Veronica Abello;Judilyn Fuentes-Duculan

  • Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    Kenneth B Gordon;Bruce Strober;Mark Lebwohl;Matthias Augustin

Frequent Co-Authors

Richard G. Langley
Richard G. Langley Dalhousie University
Kenneth B. Gordon
Kenneth B. Gordon Medical College of Wisconsin
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Kristian Reich
Kristian Reich University of Göttingen
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Craig L. Leonardi
Craig L. Leonardi Saint Louis University
Christopher E.M. Griffiths
Christopher E.M. Griffiths University of Manchester
Carle Paul
Carle Paul Federal University of Toulouse Midi-Pyrénées
Diamant Thaçi
Diamant Thaçi University of Lübeck

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are interested in medicine but want alternative education pathways, many accredited online programs offer flexible options. For nurses seeking advancement, some rn to bsn online no clinicals programs eliminate the need for on-site clinicals, making it more convenient for working professionals to earn their degree.

Those aiming for leadership or advanced practice roles might consider pursuing graduate studies. There are now shortest online dnp program options, which allow qualified nurses to obtain a Doctor of Nursing Practice quickly. Some institutions even offer easiest dnp programs that emphasize practical coursework and manageable requirements, appealing to those balancing work and study.

For those looking to enter the healthcare field faster, fast track lpn programs online enable students to become Licensed Practical Nurses in a shorter period. These pathways support a diverse range of career goals—from bedside care to advanced practice—while taking advantage of flexible, accessible online learning.

Best Scientists Citing Kim Papp

Trending Scientists

Recently Published Articles